ICON PUBLIC LIMITED COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 319.8 USD | +0.86% |
|
-2.99% | +12.97% |
Financials (USD)
| Sales 2024 * | 8.64B | Sales 2025 * | 9.31B | Capitalization | 26.44B |
|---|---|---|---|---|---|
| Net income 2024 * | 807M | Net income 2025 * | 974M | EV / Sales 2024 * | 3.31 x |
| Net Debt 2024 * | 2.18B | Net Debt 2025 * | 945M | EV / Sales 2025 * | 2.94 x |
| P/E ratio 2024 * |
32.3
x | P/E ratio 2025 * |
26.4
x | Employees | 41,150 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on ICON Public Limited Company
More recommendations
More press releases
More news
| 1 day | +0.86% | ||
| 1 week | -2.99% | ||
| Current month | -1.55% | ||
| 1 month | +1.39% | ||
| 3 months | -5.49% | ||
| 6 months | +15.96% | ||
| Current year | +12.97% |
1 week
312.19
323.48
1 month
306.62332.52
Current year
244.59344.77
1 year
221.20344.77
3 years
171.43344.77
5 years
104.28344.77
10 years
44.90344.77
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Cutler
CEO | Chief Executive Officer | 63 | 11-10-31 |
Brendan Brennan
DFI | Director of Finance/CFO | 45 | 05-12-31 |
Ciaran Murray
CHM | Chairman | 61 | 05-10-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Climax
FOU | Founder | 71 | 90-05-31 |
Stephen Cutler
CEO | Chief Executive Officer | 63 | 11-10-31 |
Linda Grais
BRD | Director/Board Member | 68 | 21-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.68% | 2 M€ | -.--% | ||
| 1.28% | 7 M€ | -.--% | - | |
| 0.91% | 4 M€ | +18.30% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-12 | 319.8 | +0.86% | 382,004 |
| 24-06-11 | 317 | -0.88% | 423,998 |
| 24-06-10 | 319.8 | +0.18% | 400,585 |
| 24-06-07 | 319.3 | -0.85% | 634,384 |
| 24-06-06 | 322 | -2.31% | 677,086 |
Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm EDT
More quotes
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Calendar
2024-07-23
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
319.8
USD
Average target price
363.6
USD
Spread / Average Target
+13.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.97% | 26.44B | |
| +48.54% | 56.61B | |
| +37.32% | 39.25B | |
| -6.02% | 39.62B | |
| -6.90% | 28.28B | |
| -16.91% | 20.12B | |
| +31.71% | 12.48B | |
| +28.18% | 12.51B | |
| +0.38% | 12.2B | |
| -9.54% | 11.02B |
- Stock Market
- Equities
- ICLR Stock
